MTD219

**MTD219** is an investigational **long-acting injectable tacrolimus** formulation being developed using Biodexa's Q-Sphera sustained-release drug delivery technology. It is intended primarily for **prevention of graft rejection** in transplant settings by providing prolonged systemic exposure to tacrolimus, a calcineurin inhibitor immunosuppressant that suppresses T-cell activation by inhibiting calcineurin-dependent transcription of interleukin-2 and other cytokines. Publicly available information indicates that MTD219 is a **small-molecule depot formulation** of tacrolimus developed by **Biodexa** and was described in company/pipeline materials as being in **preclinical to early Phase 1 development** for transplant anti-rejection use, with mechanism and target biology expected to follow those of tacrolimus.

Other names

long-acting tacrolimusQ-Sphera tacrolimus